Giovanni Gerardo C.
- Country
- Italy
- Department
- Oncologia
Research Overview
- Evaluation of Lenvatinib, Pembrolizumab, and Chemotherapy in Advanced/Metastatic Gastroesophageal Adenocarcinoma: A Phase 3 Randomized Study
- Evaluation of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Neoadjuvant/Adjuvant Treatment of Gastric and Gastroesophageal Junction Adenocarcinoma
- Phase 2/3 Evaluation of Evorpacept with Trastuzumab, Ramucirumab, and Paclitaxel in Metastatic HER2-Overexpressing Gastric/GEJ Adenocarcinoma
Data & Insights
Has run more than one trial at 62 of 190 partner sites.
Specializations
Gastric Cancer Research
The investigator specializes in treating advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma, with particular emphasis on perioperative treatment approaches.
- Locally advanced resectable gastric cancer
- HER2-overexpressing gastric tumors
- Microsatellite instability-high gastric cancer
Their research extends to novel therapeutic combinations including immunotherapy and targeted treatments for gastric cancer patients.
Esophageal Cancer Focus
The investigator conducts research in advanced esophageal carcinoma, with specific attention to both squamous cell and adenocarcinoma variants.
- Metastatic esophageal carcinoma
- Unresectable esophageal squamous cell carcinoma
- Post-chemoradiotherapy treatment strategies
Their work includes evaluation of innovative immunotherapeutic approaches for esophageal cancer treatment.
Precision Medicine Applications
The investigator focuses on biomarker-driven therapeutic approaches in gastrointestinal cancers.
- FGFR2b overexpression analysis
- HER2-directed therapy resistance
- Microsatellite instability testing
Their research incorporates targeted therapies based on specific molecular markers in gastric and esophageal cancers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.